MoCA-Norm: Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)

Sponsor

Andreas Monsch (Other)

Overall Status

Completed

CT.gov ID

NCT03246269

Collaborator

(none)

334

Enrollment

Actual Duration (Months)

Study Details

Study Description

Brief Summary

This observational cohort study in healthy volunteers establishes normative data for the German version of the Montreal Cognitive Assessment (MoCA) and investigates the possible impacts of demographics on the MoCA total score.

Condition or Disease	Intervention/Treatment	Phase
Cognitive Impairment Cognitive Decline Cognition Disorders Cognitive Symptom Cognitive Change Cognitive Deterioration Cognitive Abnormality Cognitive Impairment, Mild Cognition Disorders in Old Age Dementia Dementia Alzheimers Dementia, Alzheimer Type Dementia, Mild Dementia of Alzheimer Type	Diagnostic Test: MoCA

Detailed Description

The Montreal Cognitive Assessment (MoCA) is a short tool to evaluate a multitude of cognitive domains (visuospatial / executive functioning, object naming, memory, attention, language, abstraction, orientation). The original English MoCA consistently showed very high sensitivity and specificity in distinguishing patients with mild cognitive impairment from healthy controls. Therefore it is an excellent tool for early recognition of cognitive disorders. Based on a Canadian sample, the MoCA proposes a cut-off-value of 26/30 points. However, there is increasing evidence of intercultural differences in terms of the best cut-off-score. In addition the original version only slightly corrects for possible influences of education - an adjustment for age- or gender-related effects is missing. Therefore, the aim of our study was to investigate the possible impacts of demographics on the MoCA total score and to provide normative values for a German-speaking population.

Study Design

Study Type:

Observational

Actual Enrollment :

334 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)

Actual Study Start Date :

Dec 1, 2016

Actual Primary Completion Date :

Apr 1, 2017

Actual Study Completion Date :

Apr 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
MoCA cohort The German MoCA is administered once to all study participants.	Diagnostic Test: MoCA

Arm

Intervention/Treatment

MoCA cohort

The German MoCA is administered once to all study participants.

Diagnostic Test: MoCA

Outcome Measures

Primary Outcome Measures

Montreal Cognitive Assessment (MoCA) - German version [Baseline]
Total score of the MoCA

Secondary Outcome Measures

Mini-Mental State Examination (MMSE) [Baseline]
Total score of the MMSE
Geriatric Depression Scale (GDS) [Baseline]
Total score of the GDS
Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB) [Baseline]
Total score of the CERAD-NAB

Eligibility Criteria

Criteria

Ages Eligible for Study:

65 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Age ≥65 years
Education ≥7 years
Fluency in the German language
Written informed consent

Exclusion Criteria:

History of cognitive impairment
Depression
Severe sensory or motor impairment interfering with cognitive testing
Serious somatic disease
Disease or event affecting the central nervous system
Cerebrovascular disease
Regular medication with psychoactive drugs except for benzodiazepines
Participation in a cognitive study within the last 3 months

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Andreas Monsch

Investigators

Principal Investigator: Alessandra Thomann, MSc, Felix Platter Hospital Basel
Principal Investigator: Nicolai Goettel, MD, University Hospital, Basel, Switzerland
Principal Investigator: Raphael Monsch, MD, University Hospital, Basel, Switzerland
Principal Investigator: Manfred Berres, PhD, University of Applied Sciences Koblenz
Study Chair: Andreas Monsch, PhD, Felix Platter Hospital Basel